CAR-T Platform
WU-CART-007 has received Regenerative Medicine Advanced Therapy (RMAT), Fast Track, Orphan Drug, and Rare Pediatric Disease designations from the U.S. Food and Drug Administration and Priority Medicines (PRIME) Scheme designation in the European Union for the treatment of relapsed/refractory (R/R) T cell acute lymphoblastic leukemia (T-ALL) and T cell lymphoblastic lymphoma (T-LBL). RMAT and PRIME designations provide increased agency support to expedite the development and review of promising therapies for patients in need.
Allogeneic Cell therapy
Off-The-Shelf Manufacturing
Healthy Donor



Multiple Patients

Many doses/batch
- Reduced production time
- Young healthy donors
- Homogeneity of T-cell products
- Treatment of multiple patients from a single donor
- Stockpile inventory to ensure a consistent supply
- Point of care ready
Next in our story
Copyright © 2025 Wugen. All Rights Reserved.
Privacy Notice
a COGNEO design